Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood pressure drugs tested as COVID-19 treatment in global trial

NCT ID NCT04591210

Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether common blood pressure medications (ACE inhibitors or ARBs) could improve outcomes for high-risk COVID-19 patients. Researchers enrolled 372 adults with confirmed COVID-19 who were either over 40 (outpatients) or over 18 (hospitalized). The goal was to see if these drugs reduced the need for ICU care, ventilators, or death within 28 days, and also tracked quality of life after one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

372 people

The number who actually took part.

Started

Jan 2021

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with COVID-19 diagnosis with laboratory confirmation within the last 30 days AND * Age 40 years old or greater if outpatient OR age 18 years old or greater if inpatient (admitted to the hospital) at time of recruitment Exclusion Criteria: * Contraindication to ARB or ACEi, including severe aortic stenosis and angioedema * Patients who are currently on active treatment with ARB/ACEi * Known bilateral renal artery stenosis * Systolic BP ≤90 mmHg * eGFR\<30 ml/min, if not receiving dialysis treatment * K\>5.5 mmol/L on screening laboratory testing * Recent history of dizziness, vertigo, related to hypotension or orthostatic hypotension, that can lead to contraindication to ACEI/ARBs * Acute respiratory distress syndrome requiring invasive ventilation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases COVID -19

Contacts and locations

Locations

  • Alberta Health Services

    Edmonton, Alberta, Canada

  • Centro de Pesquisa Clinica da Unimed Campo Grande

    Campo Grande, Minas Gerais, Brazil

  • Centro de Pesquisa Clinicas Dr Marco Mota

    Maceió, Alagoas, Brazil

  • Centro de Pesquisas em Diabetes e Doencas Endocrino-Metabolicas

    Fortaleza, Ceará, 60-430-350, Brazil

  • Clinica de Campo Grande

    Campo Grande, Minas Gerais, Brazil

  • Hospital Agamenom Magalhaes

    Recife, Pernambuco, Brazil

  • Hospital Bela Vista

    Consolação, São Paulo, Brazil

  • Hospital Eduardo Campos da Pessoa Idosa

    Estância, Recife, 50870-901, Brazil

  • Hospital Felicio Rocho

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital General 1, IMSS

    Mexico City, Mexico

  • Hospital General Regional No 2

    El Marqués, Querétaro, 76269, Mexico

  • Hospital General de Zona 20

    La Margarita, Puebla, 72560, Mexico

  • Hospital General de zona 27- IMSS

    Mexico City, Mexico

  • Hospital General zona 11

    Xalapa, Veracruz, 91000, Mexico

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Hospital Sao Vicente de Paulo

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital Universitar Canoas

    Canoas, Rio Grande do Sul, Brazil

  • Hospital Universitario Sao Francisco na Providencia de Deus

    Bragança Paulista, São Paulo, 12916-542, Brazil

  • Hospital de Infectologia Dr Daniel Mendez Fernandez

    Azcapotzalco, Mexico City, 06900, Mexico

  • Hospital de Julho

    São Paulo, São Paulo, 01409-901, Brazil

  • Instituto Atena de Pesquisa Clinica

    Natal, Rio Grande do Norte, Brazil

  • Instituto Goiano de Oncologia e Hematologia

    Goiânia, Brazil

  • Instituto Prevent Senior

    São Paulo, São Paulo, Brazil

  • Instituto de Coracao

    São Paulo, São Paulo, Brazil

  • Instituto de Pesquisa Clinica de Campinas

    Campinas, São Paulo, Brazil

  • Nucleo de Pesquisa Clinica SS

    Curitiba, Paraná, 80730-150, Brazil

  • Pronto Socorro Cardiologico de Pernambuco Recife

    Recife, Pernambuco, Brazil

  • Santa Casa de Itabuna

    Itabuna, Estado de Bahia, Brazil

  • Unidad de Medicina Familiar No 10

    Xalapa, Veracruz, 91000, Mexico

  • Unidad de Medicina Familiar No 77

    Ecatepec de Morelos, State of Mexico, Mexico

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.